Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Part of paid clinical trials in Duarte, California.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT02231749
- Phase
- PHASE3
- Status
- Completed
Conditions
- Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — BIOLOGICAL
- Ipilimumab — BIOLOGICAL
- Sunitinib — DRUG
Study Details
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Key Dates
- Start date
- Oct 16, 2014
- Status verified
- May 2026
- Primary completion
- Jun 26, 2017
- Completion
- Mar 21, 2025
Study Design
- Enrollment
- 1,096 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kgNivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Active Comparator: Arm B: Sunitinib 50 mgSunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks
Primary Outcome Measure
Objective Response Rate (ORR) in Intermediate/Poor Risk Participants Per Independent Radiology Review Committee (IRRC) Using RECIST v1.1 [ Time Frame: From first dose until date of documented disease progression or subsequent therapy, whichever occurs first (assessed up to June 2017, approximately 31 months) ]
Locations (37)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 0006 | Duarte | California | 91010 | - |
| Local Institution - 0057 | La Jolla | California | 92093-0698 | - |
| Local Institution - 0035 | Los Angeles | California | 90048 | - |
| Local Institution - 0044 | Los Angeles | California | 90033 | - |
| Local Institution - 0067 | Stanford | California | 94305 | - |
| Local Institution - 0138 | New Haven | Connecticut | 06520 | - |
| Local Institution - 0034 | Washington D.C. | District of Columbia | 20007 | - |
| Local Institution - 0049 | Tampa | Florida | 33612 | - |
| Local Institution - 0068 | Atlanta | Georgia | 30322 | - |
| Local Institution - 0038 | Indianapolis | Indiana | 46202 | - |
| Local Institution - 0042 | Iowa City | Iowa | 52242 | - |
| Local Institution - 0163 | Fairway | Kansas | 66205 | - |
| Local Institution - 0004 | Baltimore | Maryland | 21287 | - |
| Local Institution - 0048 | Baltimore | Maryland | 21201 | - |
| Local Institution - 0110 | Boston | Massachusetts | 02215 | - |
| Local Institution - 0135 | Boston | Massachusetts | 02111 | - |
| Local Institution - 0161 | Boston | Massachusetts | 02215 | - |
| Local Institution - 0173 | Boston | Massachusetts | 02215 | - |
| Local Institution - 0046 | Ann Arbor | Michigan | 48109 | - |
| Local Institution - 0043 | Detroit | Michigan | 48201 | - |
| Local Institution - 0036 | Buffalo | New York | 14263 | - |
| Local Institution - 0001 | New York | New York | 10065 | - |
| Local Institution - 0008 | Charlotte | North Carolina | 28204 | - |
| Local Institution - 0045 | Durham | North Carolina | 27710 | - |
| Local Institution - 0007 | Cleveland | Ohio | 44195 | - |
| Local Institution - 0164 | Columbus | Ohio | 43210 | - |
| Local Institution - 0039 | Portland | Oregon | 97239 | - |
| Local Institution - 0054 | Allentown | Pennsylvania | 18105 | - |
| Local Institution - 0005 | Philadelphia | Pennsylvania | 19111 | - |
| Local Institution - 0031 | Pittsburgh | Pennsylvania | 15232 | - |
| Local Institution - 0055 | Charleston | South Carolina | 29425 | - |
| Local Institution - 0159 | Chattanooga | Tennessee | 37403 | - |
| Local Institution - 0066 | Nashville | Tennessee | 37203 | - |
| Local Institution - 0032 | Dallas | Texas | 75390-8852 | - |
| Local Institution - 0056 | Dallas | Texas | 75246 | - |
| Local Institution - 0003 | Houston | Texas | 77030-4009 | - |
| Local Institution - 0041 | Seattle | Washington | 98109 | - |
Related coverage on Hipa.ai
- Nivolumab/Ipilimumab Improves Renal Cell Carcinoma ORR, OS vs SunitinibNivolumab · Jun 26, 2017 · ClinicalTrials.gov
Find similar trials in Duarte, CA
By condition
Related Studies
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene MutationsPHASE2 · Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
- Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialPHASE3 · Recruiting · SWOG Cancer Research Network · Birmingham, Alabama
- Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell CarcinomaPHASE2 · Recruiting · Yale University · New Haven, Connecticut